Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymphomas

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05133505

Enrollment

Registered

2021-11-24

Start date

2002-01-01

Completion date

2021-11-01

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, B-Cell

Brief summary

Primary central nervous system diffuse large B cell lymphoma is a rare and aggressive entity of diffuse large B cell lymphoma. A previous transcriptomic study showed an overexpression of TIM-3 and Gal-9 in the tumor microenvironment. The investigators aimed to characterise TIM-3/Gal-9 immune checkpoints by using immunohistochemistry in the tumor microenvironment of primary central nervous system diffuse large B cell lymphoma.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

\- patient with a Diagnosis of LBDGC-SNC

Exclusion criteria

* immunocompromised patients * patients with a history of previous or associated low-grade lymphoma * patients with a history of systemic LBDGC with secondary localization to the SNC

Design outcomes

Primary

Measure	Time frame	Description
TIM-3 and Gal-9 immunohistochemical expression	1 day	TIM-3 and Gal-9 immunohistochemical expression by tumor and microenvironment cells

Countries

France

Outcome results